Our core focus is reducing the commercialization risk involved with early-stage life science products and technologies. Projects range from identifying the optimal markets for platform technologies that have potential applications across a variety of product or market applications, to attribute optimization analyses or competitive positioning studies. We have completed work in practically every therapeutic category and geography, including North and South America, Europe and Asia for clients ranging from start-up companies to large multinationals.

“During the past decade when I was the President of two biotech companies I engaged Susan and Tucker to help inform major commercial decisions on platform technologies and clinical-stage assets. Their rigorous, in-depth and thoughtful market research and strategic thinking about pipeline assets were invaluable in helping us make the best possible decisions. Years of experience and a devotion to objectivity make Susan and Tucker invaluable strategic partners in navigating the commercial risk and uncertainty inherent in new drug development. They harness the collective wisdom of the market, sort out conflicting opinions and biases, and provide clear direction on complex clinical and commercial decisions.”

Paul Sekhri, President and Chief Executive Officer, Lycera Corp.